Disclosures for "Solengepras (CVN424): A Novel GPR6 Inhibitor in Clinical Development as an Investigational Therapy for Parkinson’s Disease"
-
Dr. Chou has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Accordant. Dr. Chou has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Chou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advarra. Dr. Chou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbott. Dr. Chou has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Miller & Wagner, LLP . The institution of Dr. Chou has received research support from NIH. The institution of Dr. Chou has received research support from Parkinson Study Group. The institution of Dr. Chou has received research support from Neuraly. The institution of Dr. Chou has received research support from Michael J Fox Foundation. Dr. Chou has received publishing royalties from a publication relating to health care. Dr. Chou has received publishing royalties from a publication relating to health care.
-
Dr. Brice has received personal compensation for serving as an employee of Cerevance.
-
Dr. Scholl has nothing to disclose.
-
Mrs. Charles has received personal compensation for serving as an employee of Cerevance Inc..
-
Dr. Vaidya has received personal compensation for serving as an employee of Cerevance. Dr. Vaidya has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Dawson has received personal compensation for serving as an employee of Cerevance Ltd. Dr. Dawson has stock in Cerevance Ltd.
-
Dr. Carlton has received personal compensation for serving as an employee of Cerevance. Dr. Carlton has stock in Cerevance.